Non-germ cell tumors: Well circumscribed, round to lobulated
Malignant usually > 5 cm
IMAGING
F-18 FDG PET/CT Findings
MR Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Staging, Grading, & Classification
Definitions
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Reporting Tips
Selected References
Dotzauer R et al: The use of F-FDG PET/CT in testicular cancer. Transl Androl Urol. 7(5):875-8, 2018
Bouchelouche K et al: PET/computed tomography in renal, bladder, and testicular cancer. PET Clin. 10(3):361-74, 2015
Ambrosini V et al: 18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging. 41(4):668-73, 2014
Testicular cancer: What the radiologist needs to know. http://www.ajronline.org/doi/abs/10.2214/AJR.12.10319. Published June, 2013. Accessed January, 2017
Becherer A: PET in testicular cancer. Methods Mol Biol. 727:225-41, 2011
Tiemstra JD et al: Evaluation of scrotal masses. Am Fam Physician. 78(10):1165-70, 2008
Becherer A et al: FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 54(2):284-8, 2005
De Santis M et al: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 22(6):1034-9, 2004
Lassen U et al: Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 30(3):396-402, 2003
Sanchez D et al: 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. 89(9):912-6, 2002
Spermon JR et al: The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 89(6):549-56, 2002
Non-germ cell tumors: Well circumscribed, round to lobulated
Malignant usually > 5 cm
IMAGING
F-18 FDG PET/CT Findings
MR Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Staging, Grading, & Classification
Definitions
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Reporting Tips
Selected References
Dotzauer R et al: The use of F-FDG PET/CT in testicular cancer. Transl Androl Urol. 7(5):875-8, 2018
Bouchelouche K et al: PET/computed tomography in renal, bladder, and testicular cancer. PET Clin. 10(3):361-74, 2015
Ambrosini V et al: 18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging. 41(4):668-73, 2014
Testicular cancer: What the radiologist needs to know. http://www.ajronline.org/doi/abs/10.2214/AJR.12.10319. Published June, 2013. Accessed January, 2017
Becherer A: PET in testicular cancer. Methods Mol Biol. 727:225-41, 2011
Tiemstra JD et al: Evaluation of scrotal masses. Am Fam Physician. 78(10):1165-70, 2008
Becherer A et al: FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 54(2):284-8, 2005
De Santis M et al: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 22(6):1034-9, 2004
Lassen U et al: Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 30(3):396-402, 2003
Sanchez D et al: 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. 89(9):912-6, 2002
Spermon JR et al: The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 89(6):549-56, 2002
STATdx includes over 200,000 searchable images, including x-ray, CT, MR, and ultrasound images. To access all images, please log in or subscribe.